These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant. Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605 [TBL] [Abstract][Full Text] [Related]
23. Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease. Redfern J; Tu Q; Hyun K; Hollings MA; Hafiz N; Zwack C; Free C; Perel P; Chow CK Cochrane Database Syst Rev; 2024 Mar; 3(3):CD011851. PubMed ID: 38533994 [TBL] [Abstract][Full Text] [Related]
24. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline. Reece D; Imrie K; Stevens A; Smith CA; Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013 [TBL] [Abstract][Full Text] [Related]
25. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
26. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Harnan S; Kearns B; Scope A; Schmitt L; Jankovic D; Hamilton J; Srivastava T; Hill H; Ku CC; Ren S; Rothery C; Bojke L; Sculpher M; Woods B Health Technol Assess; 2024 Oct; 28(73):1-230. PubMed ID: 39487661 [TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. Liang Y; Gan L; Zeng D; Lin L; Xiong Z; Liao F; Wang A Clin Transl Oncol; 2024 Oct; 26(10):2652-2664. PubMed ID: 38671328 [TBL] [Abstract][Full Text] [Related]
28. Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report. Villatore A; Bosi C; Pomaranzi C; Cigliola A; Tateo V; Mercinelli C; Vignale D; Rizzo S; Necchi A; Peretto G Cardiovasc Toxicol; 2024 Nov; 24(11):1168-1173. PubMed ID: 39085529 [TBL] [Abstract][Full Text] [Related]
29. Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer. Vince M; Naqvi SMH; Pellini B; Verbosky M; Melzer D Lung Cancer; 2024 Dec; 198():107999. PubMed ID: 39500124 [TBL] [Abstract][Full Text] [Related]
30. Drug therapy for obstructive sleep apnoea in adults. Mason M; Welsh EJ; Smith I Cochrane Database Syst Rev; 2013 May; 2013(5):CD003002. PubMed ID: 23728641 [TBL] [Abstract][Full Text] [Related]
31. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. Tramacere I; Virgili G; Perduca V; Lucenteforte E; Benedetti MD; Capobussi M; Castellini G; Frau S; Gonzalez-Lorenzo M; Featherstone R; Filippini G Cochrane Database Syst Rev; 2023 Nov; 11(11):CD012186. PubMed ID: 38032059 [TBL] [Abstract][Full Text] [Related]
32. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602 [TBL] [Abstract][Full Text] [Related]
34. Topical fluoride as a cause of dental fluorosis in children. Wong MCM; Zhang R; Luo BW; Glenny AM; Worthington HV; Lo ECM Cochrane Database Syst Rev; 2024 Jun; 6(6):CD007693. PubMed ID: 38899538 [TBL] [Abstract][Full Text] [Related]
35. Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma. Cai L; Roos J; Miranda PAP; Liljas B; Rule S; Wang M J Med Econ; 2024; 27(1):1552-1557. PubMed ID: 39461001 [TBL] [Abstract][Full Text] [Related]
36. First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study. El Zarif T; Semaan K; Xie W; Eid M; Zarba M; Issa W; Zhang T; Nguyen CB; Alva A; Fahey CC; Beckermann KE; Karam JA; Campbell MT; Procopio G; Stellato M; Buti S; Zemankova A; Melichar B; Massari F; Mollica V; Venugopal B; Ebrahimi H; de Velasco G; Gurney HP; De Giorgi U; Parikh O; Winquist E; Master V; Garcia AR; Cutuli HJ; Ferguson TR; Gross-Goupil M; Baca SC; Pal SK; Braun DA; McKay RR; Heng DYC; Choueiri TK Eur Urol; 2024 Dec; 86(6):503-512. PubMed ID: 39147674 [TBL] [Abstract][Full Text] [Related]
37. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma. Goldkuhle M; Kreuzberger N; von Tresckow B; Eichenauer DA; Specht L; Monsef I; Skoetz N Cochrane Database Syst Rev; 2024 Dec; 12(12):CD007110. PubMed ID: 39620432 [TBL] [Abstract][Full Text] [Related]
38. Azathioprine for people with multiple sclerosis. Ridley B; Nonino F; Baldin E; Casetta I; Iuliano G; Filippini G Cochrane Database Syst Rev; 2024 Dec; 12(12):CD015005. PubMed ID: 39651635 [TBL] [Abstract][Full Text] [Related]